Outsourced Pharma App Notes & Case Studies

  1. Reducing Risk And Timelines In Cell Line Development 3/25/2025

    Accelerate your biologic development by adopting faster, more reliable clone selection methods that reduce time and resources while improving the likelihood of identifying stable, high-producing cell lines.

  2. Packing MabSelect™ And MabSelect SuRe™ Resins Using Verified Methods 12/6/2024

    Proper packing of MabSelect resins is crucial for efficient chromatography. Verified methods ensure stability, optimal flow, and reproducibility across scales using automated tools.

  3. Developing A Robust Crystallization Process For A High-Molecular-Weight Peptide 8/14/2026

    Scaling peptide crystallization is complex, with solid forms, polymorphic impurities, and solvent constraints all impacting quality and manufacturability.

  4. Expanding The OSD Toolbox: An Industry Approach To Adsorb Lipids Onto Powder Substrates 12/11/2024

    Explore innovative solutions for improving the solubility and bioavailability of poorly soluble compounds in solid oral dosage forms to enhance drug delivery and therapeutic effectiveness.

  5. High Drug Tolerance ADA Testing For Long‑Acting mAbs 5/6/2026

    See how advanced ADA assay design overcomes extreme drug interference, enabling reliable immunogenicity assessment for long‑acting, high‑dose monoclonal antibodies in early clinical development.

  6. Integrating Cutting-Edge Technologies In Cell Bank Manufacturing 7/31/2025

    Discover how our adoption of a counterflow centrifuge enhances GMP-compliant cell banking through closed-system automation, precision harvesting, and scalable workflows.

  7. Patient Adherence With A Novel Dosage Form 11/13/2025

    A sprinkle formulation helps patients with tremors or dysphagia take medication more easily, improving adherence, comfort, and care through a novel, FDA-approved oral granule format.

  8. CLD Case Study: Complex Biologics – Bispecific Fusion Nanobody 7/17/2026

    See how a bispecific fusion nanobody (BFN) achieved BsAb titers above 7 g/L with 5 of 6 clones stable beyond 60 generations — from CLD through cGMP manufacturing.

  9. Unlock 14% Reduction In AAV Gene Therapy Cost Of Goods 3/25/2026

    Comparing plasmid DNA to enzymatically produced DNA shows how enzymatic methods cut manufacturing costs, speed production, and boost efficiency for large‑scale AAV gene therapy.

  10. Formulation Development Of Enterically Protected Spray Dried Dispersions 11/17/2025

    Adrulipase spray-dried dispersions were evaluated to create an orally delivered, enteric-protected enzyme. The lead formulation provided the best acid protection, rapid release, and stability.